Drug Profile
Research programme: exosome-based peptide therapeutics - Evox Therapeutics
Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Evox Therapeutics
- Class Biological proteins; Exosome therapies; Neuroprotectants; Peptides; RNA; Small molecules
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Gaucher's disease; Hyperammonaemia
- Discontinued Infections; Neurological disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Gaucher's-disease in United Kingdom
- 28 Feb 2024 No recent reports of development identified for preclinical development in Hyperammonaemia in United Kingdom
- 28 Dec 2022 No recent reports of development identified for research development in Duchenne muscular dystrophy in United Kingdom